A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC

详细信息	查看全文 | 推荐本文 |

• 作者：H. LeCaer^a ; ^{herve.lecaer@ch-draguignan.fr} ; L. Greillier^b ; R. Corre^c ; H. Jullian^d ; J. Crequit^e ; L. Falchero^f ; C. Dujon^g ; H. Berard^h ; A. Vergnenegreⁱ ; C. Chouaid^j ; the GFPC 0505 Team¹
• 关键词：Frail elderly ; Co-morbidities ; Phase II trial ; Chemotherapy ; Lung cancer
• 刊名：Lung Cancer
• 出版年：2012
• 期刊代码：187_01695002
• 类别：med
• 出版时间：July, 2012
• 卷：77
• 期：1
• 页码：97-103
• 文件大小：267 K

摘要

Background

The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at disease progression (arm A) versus erlotinib followed by G at progression (arm B) in vulnerable elderly patients with advanced non small-cell lung cancer (NSCLC), selected on the basis of a comprehensive geriatric assessment (CGA).

Methods

Vulnerable elderly chemotherapy-naive patients with stage IIIB/IV NSCLC were selected after a CGA (socioeconomic, cognitive and emotional status, depression, nutritional status, ADL and IADL assessments). The primary endpoint was the time to second progression (TTP2). Overall survival (OS), time to first progression (TTP1) and safety were secondary endpoints.

Results

Between May 2006 and January 2010, 21 centers enrolled 100 patients, of whom 94 were eligible. TTP2 was 4.3 and 3.5 months in arm A and arm B, respectively; TTP1 was 2.5 and 2.2 months; and the median OS time was 4.4 and 3.9 months. The respective one-year survival rates were 27.3%and 20%. There was no major unexpected toxicity.

Conclusion

In vulnerable elderly patients with NSCLC not selected for EGFR expression, both strategies were feasible but had modest efficacy. Further studies are needed to identify elderly patients who should receive palliative care only.